<DOC>
	<DOC>NCT02159365</DOC>
	<brief_summary>To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.</brief_summary>
	<brief_title>Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Eastern Cooperative Oncology Group (ECOG) performance status ≤2 Documented evidence of active multiple myeloma: Newly diagnosed, not candidate for transplant Relapsed/refractory who have received up to 3 prior lines of therapy Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled: Not refractory to prior Lenalidomide which is defined as no progression while receiving Lenalidomide or within 60 days of last dose of Lenalidomide Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event (AE) Target Disease Exceptions Plasma cell leukemia Monoclonal gammopathy of undetermined significance (MGUS) Smoldering Myeloma Primary amyloidosis Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>